Zhu et al. demonstrated that activation of Sirt1 mitigated the expression of inflammatory and fibrogenic factors and also significantly suppressed the mTOR signaling in BLM-treated fibroblasts, suggesting that activation of Sirt1 may inhibit inflammation and ameliorates fibrosis in SSc patients via blocking the mTOR pathway [159]. This evidence concerns the gene SIRT1 and systemic sclerosis.